116 records found.
Nov 21, 2019
Amgen Completes Acquisition Of Otezla® (apremilast)
Nov 15, 2019
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Nov 12, 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
Nov 11, 2019
TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Nov 08, 2019
Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
Nov 07, 2019
Global Psoriasis Drugs Market Report 2019: Market was Valued at $30.13 Billion in 2018 and is Expected to Grow to $46.57 Billion
Oct 31, 2019
RINVOQ(TM) (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
Oct 18, 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Oct 12, 2019
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
Oct 09, 2019
AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress
Oct 03, 2019
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Sep 23, 2019
International Council Of Dermatologists Introduces New Method Of Determining Psoriasis Severity
Sep 17, 2019
Rheumatologist Dr. Jenny Gartshteyn Joins CORE Medical & Wellness in Lyndhurst, NJ
Sep 13, 2019
Novartis' Cosentyx and Pfizer's Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights
Sep 11, 2019
Interleukin Inhibitors Market Worth $74.6 Billion by 2026 | CAGR: 17.4%: Grand View Research, Inc.
Sep 03, 2019
Global Psoriasis Treatment Markets, 2016-2018 & 2019-2025 - Increasing Adoption of IL Inhibitors, Uptake of Biosimilars, Patent Expirations
Aug 26, 2019
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Aug 19, 2019
The global psoriatic arthritis therapeutics market at a CAGR of almost 9% during the forecast period
Aug 13, 2019
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
Aug 07, 2019
Camber Spine Announces Addition of Biologics to Its Portfolio

Pages